POMAGLUMETAD METHIONIL


Synonyms	LY-2140023 LY-2140023 MONOHYDRATE LY2140023 Ly2140023 Pomaglumetad methionil
Status
Molecule Category	UNKNOWN
UNII	3V85EZ3KFQ
EPA CompTox	DTXSID00212944


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	VOYCNOJFAJAILW-CAMHOICYSA-N
Smiles	CSCC[C@H](N)C(=O)N[C@@]1(C(=O)O)CS(=O)(=O)[C@H]2[C@H](C(=O)O)[C@H]21
InChI	InChI=1S/C12H18N2O7S2/c1-22-3-2-5(13)9(15)14-12(11(18)19)4-23(20,21)8-6(7(8)12)10(16)17/h5-8H,2-4,13H2,1H3,(H,14,15)(H,16,17)(H,18,19)/t5-,6+,7+,8-,12-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C12H18N2O7S2
Molecular Weight	366.42
AlogP	-1.87
Hydrogen Bond Acceptor	7.0
Hydrogen Bond Donor	4.0
Number of Rotational Bond	7.0
Polar Surface Area	163.86
Molecular species	ACID
Aromatic Rings	0.0
Heavy Atoms	23.0

Bioactivity

Mechanism of Action	Action	Reference
Metabotropic glutamate receptor 2 agonist	AGONIST	PubMed PubMed


Protein: Metabotropic glutamate receptor 2 Description: Metabotropic glutamate receptor 2 Organism : Homo sapiens Q14416 ENSG00000164082












Protein: Metabotropic glutamate receptor 3 Description: Metabotropic glutamate receptor 3 Organism : Homo sapiens Q14832 ENSG00000198822

Related Entries

Cross References

Resources	Reference
ChEMBL	CHEMBL2110730
FDA SRS	3V85EZ3KFQ
PharmGKB	PA165816891
PubChem	56842185
SureChEMBL	SCHEMBL1101575

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).